We found that JAK2 mutation was the most prevalent among all mutations, being present in 28 (20%) of the ET patients and 12 (60%) of the PV patients (9 had JAK2 V617F mutation and 3 had JAK2 exon 12 mutation). This evidence concerns the gene JAK2 and essential thrombocythemia.